BriaCell advances personalised skin cancer immunotherapy vaccine candidate
Around 112,000 new cases of skin cancer will be diagnosed in the US in 2026
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
BriaCell advances personalised skin cancer immunotherapy vaccine candidate
Around 112,000 new cases of skin cancer will be diagnosed in the US in 2026
LEO Pharma acquires rights for dersimelagon from Tanabe Pharma
The company will pay $435m in up front and near-term milestone payments
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
BeOne Medicines, BeOne Care Foundation and The Max Foundation renew partnership
This is to expand access to leukaemia treatment in low- and middle-income countries
CPHI Milan introduces new specialist zones
The event runs from 6-8 October 2026 at the Fiera Milano exhibition centre in Rho, Italy
Latest content
VML Health appoints Sus Misra as Executive Director, Data & Analytics
Misra previously held senior data and analytics roles at Havas Media, IPG and Publicis
Read More
Lucid Group appoints Eric Muller as CEO
Rick Sannem, outgoing CEO, transitions to Strategic Advisor to the Board
Read More
NRG Therapeutics appoints Claus Sundgreen as Chief Medical Officer
Sundgreen previously held senior medical leadership positions across biotechnology and pharmaceutical companies
Read More
Richmond Pharmacology appoints Adam Hurd as Operations Director
Hurd previously spent almost twenty years working within the NHS
Read More
Intelligence
Creating a strong patent portfolio through constant communication
Why patenting should not stop at the drug candidate stage – and why coordination between researchers and attorneys is essential for strong protection
Read More
Leading through complexity
Strengthening strategic judgement during uncertainty – exploring the strategic concepts that matter most
Read More
The Amazon reckoning: GLP-1s and the consumer lifestyle shift – why the molecule is no longer enough
Amazon’s entry into the GLP-1 market should be a signal to pharma that it needs to shift focus from molecule to ‘Operating Model’
Read More
Lupus – moving patient care beyond current therapies towards resetting the immune system
Precision medicine is no longer theoretical, but increasingly achievable for people living with lupus
Read More
Forging a connection through creativity
A spark of creativity can cut through complexity, adding real value and helping to forge true connections with patients
Read More
The UK’s life sciences’ crossroads: competing in a market defined by speed, scale and investment
The UK’s challenge is less about capability and more about how well it aligns with the way global pharma now operates
Read More
Blogs
Latest
Real Chemistry Deepens German Market Expertise with Appointment of Dirk Poschenrieder as Managing Director, Germany
August 25, 2026 | Real Chemistry|BusinessGrowth, Germany, emea, healthcarecommunications
Senior hire strengthens Real Chemistry’s ability to help healthcare clients connect global strategy to nuanced needs for in-market execution
Cutting the friction from health comms through whole-person design
August 24, 2026 | Mednet|Holistic care, Making Health Whole, Medical Communications, design thinking, med comms, whole-person health
Good design can’t change the reality of illness, remove the pain, or stop the uncertainty. But it can stop learning what comes next from being …
The Future of Decisioning
August 20, 2026 | Havas Lynx|Havas Lynx, Point.1
The traditional model for gathering insights is reaching a breaking point. Healthcare Professionals (HCPs) are increasingly time-poor and difficult to reach. Simultaneously, the costs of …
Lucid Group Names Eric Muller as Chief Executive Officer to Lead Next Phase of Growth
August 19, 2026 | Lucid Group Communications Limited|
Rick Sannem, outgoing CEO, transitions to Strategic Advisor to the Board
Treating phase 2 study design as a scientific decision is compromising launch performance, warns expert
August 17, 2026 | Nmblr|
17th August 2026 – Treating Phase 2 study design solely as a set of scientific decisions, without commercial input, is compromising launch performance, according to …
Permission to pause: making treatment breaks part of the cancer care conversation
August 5, 2026 | Cuttsy + Cuttsy|Cancer, Social Listening, Treatment breaks, Treatment pause, oncology
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
July 24, 2026 | Cuttsy + Cuttsy|EU HTA, Patient involvement, clinical trials, design
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at …
Infographic: Are data blind spots putting your launch at risk?
July 16, 2026 | Inizio|AI, Pharma, Product Launch, healthcare
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult …
Why faster trials make participant understanding more important than ever
July 15, 2026 | Cuttsy + Cuttsy|Informed Consent, clinical trials, communication
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.